Anti-metastatic effect of 131I-labeled Buthus martensii Karsch chlorotoxin in gliomas

Invertebrate venoms: A treasure trove of bioactive compounds with anticancer potential

Invertebrate venoms, despite their inherent toxicity, represent a promising source of bioactive compounds with significant anticancer properties. Historically, traditional medicines in Asia, Africa, and other regions have utilized these venoms to treat a variety of diseases, particularly those derived from scorpions, bees, wasps, and cone snails. Contemporary research has illuminated their therapeutic potential, especially in oncology. In vitro and in vivo studies demonstrate that specific toxins from these venoms can inhibit tumor cell proliferation, induce apoptosis, and restrict metastasis. The anticancer efficacy of invertebrate venoms is primarily attributed to their capacity to selectively target malignant cells while minimizing adverse effects on healthy tissues. In addition, bioactive compounds extracted from certain invertebrate venoms exhibit selective cytotoxicity against various cancer cell lines and can inhibit enzymes critical to tumor progression, thereby impeding the invasion and dissemination of cancerous cells. The increasing interest in the application of invertebrate venoms in cancer therapy has spurred further investigations into their therapeutic potential. This review critically evaluates recent scientific advancements concerning the anticancer properties of bioactive molecules derived from invertebrate venoms, elucidating their mechanisms of action and efficacy across different cancer types. We emphasize their potential as viable alternatives or adjuncts to conventional therapies, which are often constrained by their associated toxicity.

Tumor microenvironment-responsive precise delivery nanocarrier potentiating synchronous radionuclide therapy and chemotherapy against cancer

To achieve better therapeutic outcomes in cancer treatment, the combination of radionuclide and chemotherapy is commonly employed in clinical practice. However, the primary challenge lies in achieving precise drug delivery to tumor tissues, often leading to suboptimal therapeutic efficacy. This study presents a novel, tumor microenvironment-responsive drug delivery carrier that integrates real-time MRI/SPECT dual-modal imaging for precise diagnosis and treatment monitoring. The carrier comprised is based on a hybrid structure composed of hyaluronic acid (HA) and human serum albumin (HSA), encapsulating the metal-organic framework MIL-100(Fe). It was loaded with the chemotherapeutic drug doxorubicin (DOX) and modified with the radionuclide 131I, designed to precise diagnosis and treatment of tumors. HA binds specifically to the overexpressed CD44 receptor on the tumor surface, ensuring that the carrier targets tumors selectively. The incorporated 131I emits β rays, which deliver ionizing radiation to eradicate tumor cells. Concurrently, the carrier could release DOX in response to the tumor microenvironment, inhibiting DNA synthesis and sensitizing the tumor cells to radiation. This combined approach results in synchronous radionuclide therapy (RNT) and chemotherapy, maximizing therapeutic impact. In vitro and in vivo experiments demonstrated that the carrier exhibited favorable biocompatibility, stable radionuclide labeling, tumor-specific accumulation, and controlled release of DOX within the tumor microenvironment. Furthermore, MRI/SPECT dual-modal imaging enabled real-time tumor localization and monitoring of the carrier in vivo biodistribution. Experimental outcomes confirmed that this innovative carrier, combining RNT and chemotherapy, significantly inhibited tumor growth. This strategy offers a promising approach for precision radio-chemotherapy guided by dual-modal imaging, providing valuable insights for integrated targeted diagnosis and treatment of tumors.

The Significant Therapeutic Effects of Chinese Scorpion: Modern Scientific Exploration of Ion Channels

Chinese scorpion (CS), a traditional animal-based medicine used for over a millennium, has been documented since AD 935-960. It is derived from the scorpion Buthus martensii Karsch and is used to treat various ailments such as stroke, epilepsy, rheumatism, and more. Modern research has identified the pharmacological mechanisms behind its traditional uses, with active components like venom and proteins showing analgesic, antitumor, antiepileptic, and antithrombotic effects. Studies reveal that CS affects ion channels, crucial for cellular functions, through interactions with sodium, potassium, and calcium channels, potentially explaining its therapeutic effects. Future research aims to elucidate the precise mechanisms, target specific ion channel subtypes, and validate clinical efficacy and safety, paving the way for novel therapies based on these natural compounds.

Study on the knowledge, attitude and practice of single photon emission computed tomography among oncology healthcare professionals

Background

Single photon emission computed tomography (SPECT) is becoming increasingly popular in oncology. This study endeavors to scrutinize the radiation protection knowledge, attitude, and practice (KAP) exhibited by healthcare professionals involved in this imaging modality.

Methods

This cross-sectional study was conducted between September 23, 2023, and October 23, 2023, at the Second Affiliated Hospital of Anhui Medical University, the First Affiliated Hospital of Anhui Medical University, and the People's Hospital of Liuan. Demographic data and KAP scores were acquired through the administration of questionnaires.

Results

A total of 450 healthcare professionals participated in the study. Correlation analyses revealed significant positive correlations between knowledge and attitude, knowledge and practice, as well as attitude and practice. Multivariate analysis indicated that being over 40 years old was independently associated with good knowledge, as well as positive attitudes. Occupations as nurses and having no contact with SPECT patients were independently associated with a lower level of knowledge, as well as negative attitudes. Furthermore, being female, having an occupation as a nurse, and not having received relevant training were independently associated with negative practice.

Conclusion

Oncology healthcare professionals had suboptimal knowledge, negative attitude and inactive practice towards radiation protection in SPECT.

Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy

Despite breakthroughs in the development of cancer diagnosis and therapy, most current therapeutic approaches lack precise specificity and sensitivity, resulting in damage to healthy cells. Selective delivery of anti-cancer agents is thus an important goal of cancer therapy. Scorpion venom (SV) and/or body parts have been used since early civilizations for medicinal purposes, and in cultures, SV is still applied to the treatment of several diseases including cancer. SV contains numerous active micro and macromolecules with diverse pharmacological effects. These include potent anti-microbial, anti-viral, anti-inflammatory, and anti-cancer properties. This review focuses on the recent advances of SV-derived peptides as promising anti-cancer agents and their diagnostic and therapeutic potential applications in cancers such as glioma, breast cancer, prostate cancer, and colon cancer. Well-characterized SV-derived peptides are thus needed to serve as potent and selective adjuvant therapy for cancer, to significantly enhance the patients' survival and wellbeing.

Radioimmunotherapy Targeting B7-H3 in situ glioma models enhanced antitumor efficacy by Reconstructing the tumor microenvironment

Radionuclide drug conjugates (RDCs) with antibodies serve as a novel approach for the treatment of malignant tumors including glioblastoma. However, RDCs require optimal antibodies to work efficiently. Hu4G4, a novel B7-H3-targeting humanized monoclonal IgG1 antibody, is highly specific for the human B7-H3 protein (a marker of tumor cells, including glioblastoma cells). Herein, we established 131I-labeled hu4G4 (131I-hu4G4) and showed that it specifically bound to B7-H3 with high affinity (Kd = 0.99 ± 0.07 nM) and inhibited the growth of U87 cells in vitro. 131I-hu4G4 displayed potent in situ antitumor activity in a mouse model of glioma based on GL261 Red-Fluc-B7-H3 cells. More importantly, 131I-hu4G4 remodeled the tumor microenvironment and promoted the transformation of glioma from "cold" to "hot" tumors by promoting CD4+ and CD8+ T cell infiltration and the polarization of M2 to M1. Therefore, the antitumor activity observed with 131I-hu4G4, together with its ability to enhance antitumor immune responses, makes it a novel candidate for radioimmunotherapy of glioblastoma.

Preparation and radiolabeling of Iranian Androctonus crassicauda scorpion venom with technetium-99m as a new agent for cancer diagnostic and therapeutic purposes

One of the innovative methods in cancer treatment with fewer side effects is the use of active principles produced by animals and microorganisms to generate new drugs with diagnosis and treatment capability for cancer. Androctonus crassicauda scorpion venom has high potential as an anti-tumor agent and has the ability to interfere with human physiology but is still unknown. Therefore, labeling venom with radionuclides is very important to study the biological distribution of toxins for diagnostic and therapeutic purposes of various diseases, especially cancer. In this research, the toxic fraction of this venom was labeled with 99mTc. The radiochemical purity of the labeled toxic fraction was obtained by using chromatographic systems. Animal biodistribution studies were performed after injecting the labeled compound into normal rats and 4T1 breast cancer-bearing mice. The radiochemical purity of 90% was obtained for labeled compound. Biological distribution studies showed relatively rapid clearance of the labeled compound from the blood circulation system. The accumulation of the labeled compound in the liver and kidney was the highest among the organs, which could indicate the possibility of toxin excretion metabolism from liver and the kidneys. The accumulation rate of the labeled compound after 15 min was 7% in the breast cancer mass, and the ratio of the distribution of the labeled compound in the breast cancer mass to the blood was 155% at 15 min post injection. The study results indicated that scorpion venom labeling with 99mTc could be a useful tool for the biodistribution and kinetic studies of the venoms for clinical use. On the other hand, based on the results of the biological distribution of the labeled compound in tumor-bearing mice, the 99mTc-venom complex can be used as an imaging agent to diagnose breast cancer. Moreover at the same time, with some measures, it can be used as a therapeutic agent for breast cancer with more consideration. We hope that the results of this study will be a step in the future for the clinical diagnostic and therapeutic purposes of cancer using natural products.